Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is funded by PER®.

“Off-the-Shelf” Allogeneic CAR T Cells

Release Date: October 1, 2021
Expiration Date: October 1, 2022

Activity Overview

This continuing medical education (CME) activity is designed to inform health care providers about the development of “off the shelf” (allogeneic) chimeric antigen receptor (CAR) T-cell therapies for the treatment of patients with hematologic malignancies. The in-depth article will cover the rationale for using allogeneic CAR T-cell therapy, the major challenges associated with both autologous and allogeneic CAR T-cell therapies, and key data from clinical trials assessing CAR T-cell therapy. In addition, Dr Landgren will provide his views on the future of CAR T-cell therapy and on the potential role of minimal residual disease detection as a monitoring tool.

Acknowledgment of Support

This activity is funded by PER®.


Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe the major challenges surrounding the use of current chimeric antigen receptor (CAR) T-cell therapy
  • Explain the rationale for using allogeneic CAR T-cell therapy
  • Assess key data from ongoing clinical trials evaluating allogeneic CAR T-cell therapy

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Carl Ola Landgren, MD, PhD
Carl Ola Landgren, MD, PhD
Professor of Medicine
Chief of Myeloma Program
Leader of Experimental Therapeutics Program
Co-Leader of Tumor Biology Program
University of Miami
Sylvester Comprehensive Cancer Center
Miami, FL

Disclosures: Grant Research Support: Amgen, Celgene, Janssen, Takeda; Consultant:Amgen, Janssen, BMS, Pfizer, Karyopharm

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By